ArticleScientific reports2026
Avenanthramide C and chondroitin sulphate promote chondrogenic differentiation of adipose-derived mesenchymal stem cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of functional chondrocytes contributes to cartilage degeneration. Autologous transplantation of adipose-derived mesenchymal stem cells (ASCs) offers a promising approach for cartilage repair; however, current differentiation protocols remain suboptimal. To improve chondrogenic outcomes, we supplemented the standard Chondrocyte Differentiation Medium (CDM1) with Avenanthramide C (Avn C), a compound primarily known for its anti-inflammatory and chondroprotective activity. Unexpectedly, Avn C enhanced COL2A1 protein deposition, the primary collagen type that is cartilage tissue-specific. Co-administration of chondroitin sulphate (CS), a major extracellular matrix component, further elevated the expressions of important chondrogenic genes including AGGRECAN, SOX9, and LRP1. Proteomic analysis revealed increased secretion of SERPINs and complement proteins, known regulators of cartilage homeostasis and chondrocyte function, in the presence of Avn C and CS. This work identified Avn C (besides for chondroprotection) and CS as synergistic enhancers of chondrogenic differentiation in ASCs, as evidenced by the expression of articular cartilage–specific markers LRP1 and AGGRECAN, supporting their relevance for regenerative applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.